SCHEMBL190579

SCHEMBL190579

Cc1csc(Nc2cc(Oc3c(F)cccc3F)c(O)cn2)n1

nearest known ligand 0.45

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
GCK P35557 16/20 0.45
KMT2A Q03164 3/20 0.39
GAA P10253 3/20 0.39
MEN1 O00255 2/20 0.39
POLB P06746 2/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL191716 0.87 GAA (0.47) GCKKMT2AGAAMEN1ALDH1A1
SCHEMBL191325 0.87 GCK (0.54) GCKKMT2AGAAMEN1ALDH1A1
SCHEMBL12305698 0.85 GCK (0.42) GCK
SCHEMBL190743 0.85 GCK (0.44) GCKKMT2AGAAMEN1ALDH1A1
SCHEMBL12305693 0.85 GCK (0.56) GCKKMT2AGAAMEN1RAB9A
Hydrochloric Acid SCHEMBL226976 0.85 GCK (0.41) GCK
Hydrochloric Acid SCHEMBL190845 0.84 GCK (0.55) GCKKMT2AGAAMEN1RAB9A
SCHEMBL12305694 0.83 GCK (0.51) GCKKMT2AGAAALDH1A1MAPT
Hydrochloric Acid SCHEMBL190910 0.83 GCK (0.50) GCKKMT2AGAAALDH1A1MAPT
SCHEMBL12305696 0.82 GCK (0.51) GCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1986645-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2012-01-04 EP disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
EP-1986645-A1 GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2008-11-05 EP disclosed
WO-2007089512-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247526-A1 GLUCOKINASE ACTIVATORS GCKR, GCK, GALK1 GCK 2/4885KMT2A 2715/4885GAA 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.